Pathologist Interpretation

What the laboratory says this test is for

This assay interrogates simultaneously the immunoglobulin kappa (IGK), the immunoglobulin heavy chain (IGH), the T-cell receptor beta (TCRB) and the T-cell receptor gamma (TCRG) genes by PCR methods based on the BIOMED-2 consensus. This combination assay will be most useful in diagnosing mixed B-cell and T-cell atypical infiltrates and for lineage identification in poorly differentiated or immature lymphoid malignancies.

What the laboratory says this test is for

This test, which interrogates both the T-cell receptor beta locus (TCRB) by a PCR method based on the BIOMED-2 consensus, is useful for establishing clonality of T-cell lymphoid neoplasms and identification of minimal residual disease or early recurrence in patients with a previous diagnosis of a T-cell neoplasm. It can be used in association with T-cell receptor (TCR) gamma PCR assay (Test code 90509), since false-negative results can occur in up to 5-10% of T-cell malignancies with TCRB PCR alone.

What the laboratory says this test is for

This test, which interrogates both the T-cell receptor beta (TCRB) locus and the T-cell receptor gamma (TCRG) locus by a PCR method based on the BIOMED-2 consensus, is useful in patients with suspected T-cell malignancies or to evaluate for residual disease after treatment. Several published studies have demonstrated that the combination of TCRB and TCRG PCR using the BIOMED-2 method can detect virtually all clonal T-cell populations.

What the laboratory says this test is for

This assay which interrogates the T-cell receptor gamma locus (TCRG) by a PCR method based on the BIOMED-2 consensus, is used for establishing clonality of T-cell lymphoid neoplasms and identification of minimal residual disease or early recurrence in patients with a previous diagnosis of a T-cell neoplasm. It can be used in association with T-cell receptor beta (TCBR) PCR assay (Test code 91446 or TCRG/TCRB combo test code 91445), since false-negative results can occur in up to 5-10% of T-cell malignancies when testing TCRG PCR only.